All In MedTech

Device Trial Radar · NCT06853990

Innovative Automated Insulin Delivery System for Type 2 Diabetes

A Single-arm Trial With an Innovative Automated Insulin Delivery System for Type 2 Diabetes ("Twiist-T2D")

Last checked: Nov 20, 2026Latest source record: Jun 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

307

Actual

Start

Apr 14, 2025

Primary completion

Feb 25, 2026

Study completion May 6, 2026

Sponsor

Lead sponsor
Deka Research and DevelopmentNot on our public-company list
Sponsor type
Industry
Collaborators
Sequel Med Tech
First posted
Mar 3, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if the twiist insulin delivery system works to treat adults with insulin-treated type 2 diabetes.

Conditions

  • Type 2 Diabetes
  • Insulin Treated Type 2 Diabetes Mellitus

Interventions

  • twiist insulin delivery systemDevice

    twiist system includes a novel insulin pump, a CGM sensor and the DEKA Loop algorithm

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in HbA1cTime frame: Baseline to 13-weeks

Locations

30 sites in 1 country. Site status is shown where the registry gives one.

  • Scripps Whittier Diabetes Institute

    La Jolla, California

  • Hoag Memorial Hospital Presbyterian

    Newport Beach, California

  • Sansum Diabetes Research Institute

    Santa Barbara, California

27 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.